Structure Therapeutics Appoints Ted W. Love, M.D., to Board of Directors
August 03 2023 - 4:32PM
Structure Therapeutics Inc. (NASDAQ: GPCR), a clinical-stage global
biopharmaceutical company developing novel oral small molecule
therapeutics for metabolic and pulmonary diseases, today announced
that it has appointed Ted W. Love, M.D., to its Board of Directors.
Dr. Love brings more than 30 years of experience in the
biopharmaceuticals industry, and currently chairs the Biotechnology
Innovation Organization (BIO) Board. He recently served as
President and Chief Executive Officer of Global Blood Therapeutics
until its acquisition by Pfizer in 2022.
“Ted has a deep passion for making medicines
accessible to all and has spent much of his accomplished career
focused on addressing healthcare disparities and bringing
innovative breakthrough treatments to patients,” said Raymond
Stevens, Ph.D., Founder and CEO of Structure Therapeutics. “His
experience building successful biotechnology companies and his
insight as a cardiologist provide tremendous value in achieving
Structure Therapeutics’ mission of making differentiated medicines
accessible to patients around the world.”
“The focus of Structure Therapeutics on replacing
biologics and peptides with oral small molecules could
significantly improve access of important medicines to patients
around the world with chronic diseases such as diabetes and obesity
and could help address some of today’s largest global healthcare
needs,” said Dr. Love. “I look forward to working with the team to
move these programs forward and maximize the potential of their
unique structure-based drug discovery platform.”
Dr. Love joined Global Blood Therapeutics in 2014
and oversaw the development and FDA approval of Oxbryta® for sickle
cell disease. Previously, Dr. Love held executive positions at Onyx
Pharmaceuticals, Nuvelo and Theravance. Earlier in his career he
held a number of senior management positions at Genentech, where he
oversaw the development strategy and execution that led to the
approvals of six innovative medicines. Dr. Love is the current
Chair of the Biotechnology Innovation Organization (BIO) Board and
previously served as BIO’s Chair of the Emerging Companies Section
Governing Board, and Vice Chair of BIO’s Health Section Governing
Board. He is also a Board member at Seagen Inc. and Royalty Pharma
plc. Dr. Love holds a B.A. in molecular biology from Haverford
College and an M.D. from Yale Medical School. He completed a
residency in internal medicine and a fellowship in cardiology at
the Massachusetts General Hospital.
About Structure
TherapeuticsStructure Therapeutics is a leading
clinical-stage biopharmaceutical company focused on discovering and
developing innovative oral treatments for chronic metabolic and
pulmonary conditions with significant unmet medical needs.
Utilizing its next generation structure-based drug discovery
platform, the company has established a scientifically-driven,
GPCR-targeted pipeline, featuring two wholly-owned proprietary
clinical-stage small molecule compounds designed to surpass the
limitations of traditional biologic and peptide therapies and be
accessible to more patients around the world. For additional
information, please visit www.structuretx.com.
Forward-Looking StatementsThis
press release contains “forward-looking statements” within the
meaning of the “safe harbor” provisions of the Private Securities
Litigation Reform Act of 1995. All statements other than statements
of historical fact are statements that could be deemed
forward-looking statements, including, without limitation,
statements concerning the Company’s future plans and prospects, the
ability of GSBR-1290 to treat type 2 diabetes, obesity or related
indications, and expectations regarding an oral development
candidate targeting GLP-1R. In addition, when or if used in this
press release, the words “may,” “could,” “should,” “anticipate,”
“believe,” “estimate,” “expect,” “intend,” “plan,” “predict” and
similar expressions and their variants, as they relate to the
Company may identify forward-looking statements. Forward-looking
statements are neither historical facts nor assurances of future
performance. Although the Company believes the expectations
reflected in such forward-looking statements are reasonable, the
Company can give no assurance that such expectations will prove to
be correct. Readers are cautioned that actual results, levels of
activity, safety, performance or events and circumstances could
differ materially from those expressed or implied in the Company’s
forward-looking statements due to a variety of risks and
uncertainties, which include, without limitation, risks and
uncertainties related to the Company’s ability to advance
GSBR-1290, LTSE-2578, ANPA-0073 and its other therapeutic
candidates, obtain regulatory approval of and ultimately
commercialize the Company’s therapeutic candidates, the timing and
results of preclinical and clinical trials, the Company’s ability
to fund development activities and achieve development goals, the
impact of global pandemics, inflation, supply chain issues, rising
interest rates and future bank failures on the Company’s business,
its ability to protect its intellectual property and other risks
and uncertainties described in the Company’s filings with the
Securities and Exchange Commission (“SEC”), including the Company’s
quarterly Report on Form 10-Q filed with the SEC on May 11, 2023
and future reports the Company may file with the SEC from time to
time. All forward-looking statements contained in this press
release speak only as of the date on which they were made and are
based on management’s assumptions and estimates as of such date.
The Company undertakes no obligation to update such statements to
reflect events that occur or circumstances that exist after the
date on which they were made, except as required by law.
Contacts:
Investors:Jun Yoon, Chief
Financial OfficerStructure Therapeutics Inc.ir@structuretx.com
Media:Dan
Budwick1ABDan@1abmedia.com
Structure Therapeutics (NASDAQ:GPCR)
Historical Stock Chart
From Apr 2024 to May 2024
Structure Therapeutics (NASDAQ:GPCR)
Historical Stock Chart
From May 2023 to May 2024